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Abstract
Background: Targeting of the renin angiotensin system (RAS) reduces tumour growth in experimental models of
cancer. We aimed to establish if combined targeting of the ‘classical’ and ‘alternative’ arms of the RAS could result
in synergistic inhibition of colorectal cancer (CRC) liver metastases.
Methods: Immediately following induction of CRC liver metastases through intrasplenic injection of murine CRC
cells, treatment with irbesartan (AT1R blocker; 50 mg/kg/day s.c.), captopril (ACE inhibitor; 750 mg/kg/day i.p.),
CGP42112A (AT2R agonist; 0.6 μg/kg/hr i.p.), and/or ANG-(1-7) (24 μg/kg/hr i.p.) began and continued for 21 days.
Liver to body weight ratio and/or stereology were used as a measure of tumour burden. Immunohistochemistry
was used to determine AT1R and VEGF expression as well as proliferation (Ki67), apoptosis (active caspase 3) and
angiogenesis (CD34).
Results: Combined RAS therapies failed to improve upon single arm therapies. However, while irbesartan
previously inhibited tumour growth in this model, in the current experiments irbesartan failed to affect tumour
burden. Subsequent analysis showed a cancer-cell specific upregulation of the angiotensin II type I receptor (AT1R)
in irbesartan-insensitive compared to irbesartan-sensitive tumours. The upregulation of AT1R was associated with
an increase in proliferation and VEGF expression by cancer cells. While animals bearing irbesartan-sensitive tumours
showed a marked decrease in the number of proliferating cells in the liver and VEGF-expressing infiltrating cells in
the tumour following AT1R treatment, these were unchanged by treatment in animals bearing irbesartan-
insensitive (high AT1R expressing) tumours.
Conclusions: Although the results do not support increased efficacy of combined treatment, they provide
intriguing evidence of the importance of RAS expression in determining patient response and tumour growth
potential and suggest that components of the RAS could be used as biomarkers to aid in patient selection.
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Background
Metastasis to the liver is the leading cause of death in
patients with colorectal cancer (CRC)[1]. We previously
showed that targeting of the renin angiotensin system
(RAS) with either an angiotensin (ANG) II type I recep-
tor (AT1R) blocker (irbesartan) or an angiotensin con-
verting enzyme (ACE) inhibitor (captopril) could inhibit
tumour growth in an orthotopic syngeneic mouse model
of CRC liver metastases [2,3]. ACE is responsible for
converting inactive ANG I into the key active peptide of
t h ec l a s s i c a lR A S ,A N GI I .T h eA T 1 Rm e d i a t e s
proliferative, proinflammatory, and angiogenic effects of
ANG II [4,5].
The RAS also has an ‘alternative’ pathway which
counteracts many of the actions induced by ANG II-
AT1R signalling. The alternative ANG II receptor (the
AT2R) generally exerts actions antagonistic to the AT1R
including inhibition of proliferation and promotion of
apoptosis [6]. ACE2, a homologue of ACE, generates a
second RAS peptide, ANG-(1-7), directly from ANG II.
ANG-(1-7), through its specific receptor MasR, also
appears to counteract many of the actions induced by
the classical AT1R/ANGII RAS pathway [7]. Activation
of the alternative ANG II receptor, the AT2R, has been
shown to inhibit tumour growth (although to lesser
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any medium, provided the original work is properly cited.extent then either irbesartan or captopril)[5]. ANG-(1-7)
can also be infused to reduce tumour growth in several
experimental cancer models [8,9]. Two independent
Phase I clinical trials are examining ANG-(1-7) [10] and
AT1R blockade [11] in the treatment of various solid
tumours.
Given the counter-regulatory actions of the classical
and alternative RAS pathways we hypothesized that
combining inhibition of the classical RAS (AT1R block-
ade or ACE inhibition) with activation of the alternative
RAS (ANG-(1-7) infusion or AT2R activation) would
synergistically inhibit tumour growth.
Methods
In vivo model and cell lines
The mouse colorectal cancer (MoCR) cell line used for
in vivo experiments was harvested from a dimethylhy-
drazine-induced colon carcinoma in a CBA mouse at a
stage known to metastasise to the liver [12]. Liver
metastases were induced as described previously [3,12].
Briefly, 25000 MoCR cells were injected into the spleen
of 6 to 8 week old male CBA mice and, after 3 minutes,
the spleen removed to confine metastases to the liver. A
minimum of 5 animals per group were used, in treat-
ments inducing fewer tumours sample size was
increased to 10. All experiments were approved by the
Austin Health Animal Ethics Committee. Liver samples
were collected and fixed in fresh 4% PFA.
Drugs/agents and treatments
In vivo treatments included ANG-(1-7) (Auspep, 2588;
24 μg/kg/hr), CGP42112A (AT2R agonist, Sigma-
Aldrich, C160; 0.6 μg/kg/hr), and/or telmisartan (AT1R
blocker, Sigma-Aldrich, T8949; 12.5 μg/kg/hr) infusion
(Alzet
® osmotic mini pumps 1004) or s.c. daily injec-
tions of irbesartan (AT1R antagonist, Bristol-Myers
Squibb) at 50 mg/kg. Captopril was given as daily i.p.
injections of 750 mg/kg (Sigma-Aldrich, 21751). Doses
were based on previously published studies [3,5,13-15].
The solubilising agent (saline or methyl cellulose) pro-
vided a control. Treatments continued from the time of
tumour induction to tissue collection at day 21.
Immunohistochemistry
AT1R (rabbit polyclonal against human, Santa Cruz, sc-
1173), proliferation (Ki67; rat monoclonal anti-mouse,
Thermoscientific, RM-9106-S1), apoptosis (active cas-
pase 3; rabbit polyclonal anti-human, R&DSystems
AF835), angiogenesis (CD34, neovascularisation marker;
monoclonal rat anti-mouse, Abd Serotec MCA18256),
and VEGF (rabbit polyclonal anti-human, CalBiochem,
PC315) were assessed in PFA-fixed paraffin embedded
tissues. Specificity of AT1R and VEGF antibodies was
confirmed by western blot (data not shown). AT1R was
used at a concentration of 0.5 μg/ml, Ki67 at 1:100 dilu-
tion (dilution provided with manufacturer’s datasheet),
active caspase-3 at 1.0 μg/ml, CD34 at 0.1 μg/ml, and
VEGF at 1.5 μg/ml. Non-immunized rabbit IgG (Santa
Cruz, sc-2027) at an equivalent concentration to the pri-
mary target antibody was used as a negative control.
Endogenous peroxidases were blocked with 3% H2O2
and non-specific binding inhibited with 10% normal
goat serum (Zymed, 01-6201). Slides were incubated
with primary antibodies at 37°C for 1 hour and then 4°C
overnight. Slides were then incubated with the second-
ary antibody (Dako Envision
+ Goat anti-rabbit HRP sec-
ondary 4011 for AT1R, Ki67, caspase 3, and VEGF and
the Rat on Mouse AP-polymer kit (Biocare Medical;
RT518H) for CD34 for 1 hour at 37°C before visualisa-
tion with DAB or, for CD34, Vulcan fast red (Applied
Medical FR805H). Slides were counterstained with
Mayer’s haematoxylin.
Images of stained tumours were taken using digital
light microscope (Nikon Coolscope
®, Nikon Corpora-
tion, Japan) at between 40x and 400x magnification
(with a scale bar for size calibration) and were analysed
using Image-Pro plus (version 5). Depending on the ani-
mal and its tumour load, between 10 and 30 images
across 1 to 5 tumours were taken for analysis. AT1R
staining was assessed in control tissues, while VEGF,
Ki67, caspase3, and CD34 were all examined in control
and irbesartan treated tissues. Where possible, the num-
ber of positive cells out of the total number of cells was
used to measure changes in protein levels/content. A
scoring system was used to quantify differences in the
strength and abundance of AT1R and VEGF staining in
tumours. The intensity of immune-reactive staining was
evaluated subjectively (by two independent researchers)
using the intensity of immunoreactive colour develop-
ment as an measure of relative protein content. Strong
staining of many/most cells was given a grade of 5 redu-
cing to no staining (0). Only areas of viable tumour
were considered in analysis. A subpopulation of intense
VEGF expressing infiltrating cells was also counted and
is expressed as the number of positive cells per area
tumour. Ki67 and active caspase3 were assessed as both
the area of proliferating tumour (4x magnification) and
the number of proliferating cells per area tumour or
liver (20x magnification). CD34 was assessed as the
length of positively stained endothelium per tumour
area and provide an indication of the angiogenic poten-
tial of these tumours.
Statistical analyses
Quantitative data are presented as mean ± SEM or box-
plots showing the minimum value, first quartile, median,
third quartile and maximum value. Statistical analyses
were conducted using SPSS (Statistical Package for the
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(2003). Normally distributed data were assessed by
ANOVA. Mann-Whitney U test were used for non-
parametric data sets. A probability (P) value of less than
0.05 was considered as statistically significant.
Results
Captopril and ANG-(1-7) inhibited tumour burden while
AT1R blockade had no significant effect
Mice were induced with CRC liver metastases and trea-
ted with irbesartan, ANG-(1-7), or captopril while con-
trol received vehicle (PBS or methyl cellulose). Liver-to-
body weight ratio was used as a measure of liver tumour
burden. No significant differ e n c eb e t w e e nt h ec o n t r o l
and the irbesartan treated group was detected (Figure
1A). Given that we had previously found irbesartan
inhibited tumour growth in this model [3] we decided
to test another AT1R blocker, telmisartan (also pre-
sented in Figure 1A); however, again there was no sig-
nificant difference between control and telmisartan
treated groups. We also decided to examine tumour
burden by quantitative stereology as this provides a
more sensitive measure of tumour load. However, as
with the liver to body weight ratio, no significant differ-
ence was seen in the response of tumours to either irbe-
sartan (Figure 1B) or telmisartan (data not shown),
while we confirmed the ANG-(1-7)-associated reduction
in tumour growth (P = 0.00263, t-test unequal variance)
(Figure 1B).
ACE inhibition with captopril was found to retain its
anti-tumour activity (Figure 1A). Captopril-treated ani-
mals had significantly lower liver-to-body weight ratios
(0.312 ± 0.010) compared to the control group with
(0.139 ± 0.011) (P =2 . 9 0 7x1 0
-8, t-test equal variance).
The level of tumour inhibition achieved by captopril
treatment in the current experiment is comparable to
our previously published studies [2,3].
Combination therapies targeting the RAS did not improve
upon levels of tumour inhibition achieved through single
arm therapies
Although irbesartan alone did not significantly inhibit
tumour growth, we continued with the initial aim of
combining AT1R blockade and/or captopril with ANG-
(1-7) infusion. As with the single captopril treatment,
combined treatment with captopril and ANG-(1-7) sig-
nificantly inhibited tumour growth (Figure 2). However,
there was no difference between the level of inhibition
achieved by captopril alone (liver to body weight ratio
of 0.139 ± 0.11) compared to combined captopril plus
ANG-(1-7) (liver to body weight ratio of 0.149 ± 0.02).
Irbesartan plus ANG-(1-7) failed to decrease tumour
burden (Figure 2); this is despite the fact that ANG-(1-
7) alone resulted in a reduction in liver to body weight
ratio (Figure 1A and 1B). Similarly, AT2R activation
with CGP42112A combined with AT1R blockade by tel-
misartan failed to decrease tumour burden despite pre-
viously reported CGP42112A-induced inhibition of CRC
liver metastases [5].
AT1R immunostaining increased in cancer cells from
irbesartan-insensitive compared to irbesartan-sensitive
animals
While irbesartan was previously found to inhibit tumour
growth in this mouse model of CRC liver metastases, in
the current experiment, it failed to reduce liver tumour
burden despite the same experimental protocols being
employed. We hypothesized that this difference was
likely due to either to the animals used, which although
of the same strain, sex, and age were obtained 2 year
apart, or to the cell line, which again may have acquired
changes over the intervening years between experiments.
Immunohistochemistry was used to assess the relative
level and extent of AT1R expression in CRC-derived
tumours growing in the liver from both studies. While
no obvious difference was seen in the liver surrounding
tumours, tumours from the current study showed a
marked upregulation of AT1R expression. AT1R stain-
ing in cancer cells was found to be higher in the irbesar-
tan-insensitive animals compared to the irbesartan-
sensitive animals (Additional file 1 and Figure 3). Pair-
wise comparisons between tumours of different sizes all
showed higher AT1R expression in irbesartan-insensitive
tumours (AT1R
HI)c o m p a r e dt oi r b e s a r t a n - s e n s i t i v e
tumours (AT1R
LOW)( s m a l lt u m o u r s :3v s2 ,P = 0.002;
medium tumours score: 4 vs 2, P < 0.0001; large
tumours: 4 vs 2, P < 0.0001 respectively, Mann-Whitney
U test).
Within the liver there were AT1R positive cells in
both irbesartan-sensitive and irbesartan-insensitive ani-
mals. A majority of these cells co-stain with the F4/80
macrophage marker (data not shown). The number and
intensity of non-paranchymal, non-cancer cell associated
AT1R staining did not appear to differ between the irbe-
sartan-sensitive and the irbesartan-insensitive animals.
Proliferation of cancer cells was markedly increased in
the AT1R
HI cancers
AT1R
HI tumours were associated with a marked
increase (between a 17% to 32% increase) in prolifera-
tion compared to AT1R
LOW tumours (Figure 4A and
4B). This was significant for all comparisons (P ≤
0.0052, t-test) when measured as the number of prolifer-
ating cells, but was a trend when measured as the area
of proliferation (AT1R
HI control compared to AT1R
LOW
control, Figure 4A). Neither hi- nor low-AT1R-expres-
sing tumours showed a reduction in proliferation with
irbesartan treatment. This corresponds with previously
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Figure 1 Liver to body weight ratio 21 days after tumour inoculation with continuous RAS-targeted single treatments (A). Percent liver
metastases for irbesartan and ANG-(1-7) or control (untreated) animals from the same study as above (B). Telmisartan and irbesartan are AT1R
blockers, while captopril is an ANCE inhibitor. n = 5 or 6 for each group. Significant P values between 0.01 and 0.05 are shown with an *, those
less than 0.01 are shown with **. Data are presented as mean ± S.E.M.
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increase in apoptosis with irbesartan, but no change in
proliferation (Additional file 2).
In contrast to the increase in cancer-cell proliferation
by AT1R
HI tumours, the liver surrounding these
tumours had fewer (P ≤ 0.0327, t-test) proliferating cells
compared to animals bearing AT1R
LOW tumours (Figure
4C). Moreover, there was a marked reduction (P ≤
0.0002, t-test) in the number of these proliferating cells
with irbesartan treatment in the AT1R
LOW, but not the
AT1R
HI tumour-bearing animals. It is not clear what
type of cell is represented, but both non-paranchymal
and paranchymal cells were present in the proliferating
population and based on morphology and location rela-
tive to the sinusoids, these cells are likely to be hepatic
stellate cells or metastasizing tumour cells. Indeed, in
our previous study we showed that irbesartan could
reduce the number of metastatic lesions [3].
Apoptosis was increased by irbesartan treatment in both
AT1R
HI and AT1R
LOW tumours
Irbesartan treatment significantly increased the number
of apoptotic cells in both AT1R
HI tumours (P = 0.0291,
t-test) and AT1R
LOW tumours (P = 0.0144) (Figure 5).
Although this increase was not as great in the AT1R
HI
tumours compared to that seen in the AT1R
LOW
tumours. Both treated and non-treated AT1R
HI tumours
showed higher levels of apoptosis than their correspond-
ing AT1R
LOW tumours (P ≤ 0.000, t-test).
VEGF expression was higher in AT1R
HI compared to
AT1R
LOW tumours
Similar to cancer-cell proliferation, cancer cell VEGF
expression was significantly higher in AT1R
HI tumours
compared to their corresponding AT1R
LOW tumours (P
≤ 0.000, t-test) (Figure 6A). Interestingly, the median
level of VEGF intensity was higher for both irbesartan
treated groups (although this failed to reach
significance).
While cancer cell-associated VEGF was higher in the
AT1R
HI tumours (P ≤ 0.0123, t-test), the number of
intense-staining infiltrating cells was highest in the
AT1R
LOW tumours and this was decreased by irbesartan
treatment (P = 1.109 x 10
-5) (Figure 6B).
CD34+ (angiogenic) vessels were increased in AT1R
HI
tumours and decreased by irbesartan treatment in both
AT1R
HI and AT1R
LOW tumours
Our unpublished data from previous studies (Additional
file 3) showed that ANGII infusion increased the length
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decreased CD34+ endothelium compared to tumours
from control (untreated) animals. Here we also found
that irbesartan decreased the length of CD34+ endothe-
lium in tumours and that this was the case regardless of
cancer cell AT1R expression level (Figure 7). Similar to
the increase in apoptosis, the decrease in CD34 staining
was greatest in the AT1R
LOW tumours (P = 0.0267 for
AT1R
HI compared to P = 0.0179 for AT1R
LOW
tumours). However, both treated and non-treated
AT1R
HI tumours had more angiogenic vessels than
AT1R
LOW tumours (P ≤ 0.000, t-test).
Discussion
Blockade of the classical RAS through AT1R blockade
or ACE inhibition reduces tumour growth in several
experimental mouse models of cancer [2,3,16,17]. Con-
versely activation of the alternative RAS, through ANG-
(1-7) infusion [8] or AT2R activation [5], can also
reduce tumour growth. We sought to determine if
greater inhibition of tumour growth could be achieved
through dual targeting of the RAS - inhibition of the
classical RAS with simultaneous activation of the
a l t e r n a t i v eR A S .W h i l e ,w ew e r eu n a b l et os h o wa n y
benefit for combined RAS treatments, we found that an
u p r e g u l a t i o no ft h eA T 1 Rb yt h ec a n c e rc e l ll i n er e n -
dered them insensitive to AT1R blockade. These same
cells, however, remained sensitive to ACE inhibition,
suggesting significant differences in the molecular
mechanisms by which these agents inhibit tumour
growth.
The anti-tumour effects of AT1R blockers have been
well documented [3,18,19]. However, in our experiment,
irbesartan, when used alone or in combination with
ANG-(1-7) infusion, failed to decrease tumour growth.
We also tested the potent AT1R blocker telmisartan,
which has been utilised as an anti-cancer agent in other
experimental models where it was shown to be effective
[16,20,21], but again we found no benefit of treatment
compared to control animals. The lack of an effect of
AT1R blockade also contradicts a previous study con-
ducted in our laboratory using the same experimental
protocols [3].
To further investigate this finding we performed
immunohistochemical analysis on tumours from both
studies (for which tissues had been collected in the
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LOW tumours which, because of the reduced tumour load, had additional samples (n of 10). Between 10 and 30
images were taken from each mouse across 1 to 5 tumours (dependent on tumour load). Representative images are shown below.
Representative images are shown to the right. Significant P values between 0.01 and 0.05 are shown with an *, those less than 0.01 are shown
with **. Data are presented as mean ± S.E.M.
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Page 10 of 12same experimental manner). AT1R expression by cancer
cells from animals insensitive to AT1R blockade showed
a marked increase in immunohistochemical staining
compared to tissues collected from our previous irbesar-
tan sensitive animals. These results suggest that cancer
cells could be rendered insensitive to AT1R blockade
through an upregulation of the AT1R. Moreover, despite
strong AT1R expression by liver macrophages described
here and elsewhere [22] and the importance of macro-
phages during tumour progression [23], our results sug-
gest that cancer cell AT1R expression can overcome any
macrophage-mediated antitumour activity associated
with AT1R blockade.
The AT1R is also known to regulate angiogenesis,
migration, and apoptosis all of which could contribute to
regulating tumour growth [24,25]. Thus, it is likely that
the upregulation of AT1R is, at least in part, responsible
for the resistance of these cells to AT1R blockade. In sup-
port of this we found that high AT1R-expressing tumours
had increased cancer cell proliferation, higher levels of
cancer cell-associated VEGF and tumour-associated angio-
genesis. Interestingly, irbesartan lead to a slight increase in
VEGF levels in both tumour types. This is in contrast to
some studies of breast cancer [26,27], but supports our
previous study which showed that, in these tumours, acti-
vation of the AT2R increased VEGF expression [5]. Clere
et al. (2010) similarly found that in fibrosarcoma, the
AT2R could promote cancer cell VEGF production [28].
AT2R expression has also been documented in blood ves-
sels of human pituitary adenomas [29] and both the AT1R
and AT2R stimulate VEGF secretion by rat pituitary
tumour cells [30]. Thus, it would appear that in at least
some cancer-associated circumstances the AT2R can also
be proangiogeneic. However, angiogenesis (as measured
by CD34 staining) was decreased by irbesartan and this
appeared to be associated with a decrease in the number
of infiltrating VEGF-expressing cells.
We also report an increase in apoptosis and a decrease
in angiogenic vessel formation associated with irbesartan,
and while still present in AT1R
HI tumours, these effects
were less than that seen for AT1R
LOW tumours. Addi-
tionally, while it is apparent that cancer-cell AT1R
expression has a direct effect on cancer cell proliferation,
VEGF-expression, and apoptosis, we also saw marked
changes in the surrounding liver and in cells infiltrating
the tumours. In particular, irbesartan sensitive tumours
(AT1R
LOW) when untreated (i.e. control animals) were
associated with higher numbers of VEGF-infiltrating cells
in tumours and higher numbers of proliferating cells in
the liver surrounding tumours. Both of these phenomena
were reduced by irbesartan treatment. These results
would suggest that while tumour resistance was con-
ferred by higher cancer cell-AT1R expression (and that
this was associated with certain growth advantages such
as increased proliferation and reduced treatment-asso-
ciated apoptosis), the non-parenchymal cells in the liver
may be important in determining the response of low
AT1R-expressing tumours to irbesartan.
In contrast to AT1R blockade, ACE inhibition by cap-
topril maintained its effectiveness, consistent to the pre-
vious findings [3]. This suggests that ACE inhibitors,
other than blocking the production of ANG II which
subsequently binds AT1R, also generate anti-tumour
effects through non-ANG II mediated pathways. Indeed
this has been documented in several studies where
matrix metalloproteinases and vascular endothelial
growth factor expression have been recognised as non-
RAS dependent targets of ACE inhibition [31-33].
Conclusions
This research initially set out to determine if AT1R
blockade or ACE inhibition in combination with either
ANG-(1-7) or AT2R activation could lead to synergistic
inhibition of CRCLM. While we failed to show any ben-
efit of combined targeting of the RAS, our results were
fortuitous in providing insight into both the importance
of differences between the mechanisms of action of
ACE inhibition and AT1R blockade as well as the
potential of RAS expression as a biomarker.
Additional material
Additional file 1: Table indicating the intensity of AT1R staining by
different CRC liver metastases. AT1R staining scores in tumours from
animals showing insensitivity to irbesartan treatment and animals in
which irbesartan successfully inhibited tumour growth (irbesartan-
sensitive). All treatment protocols including agent dose and timing,
cancer cell numbers (and type -expecting AT1R expression as described
below) and method of induction, as well as tissue collection and
processing were identical between experiments.
Additional file 2: Figure showing proliferation and apoptosis of
cancer cells from irbesartan-sensitive tumours. Proliferation of cancer
cells from irbesartan-sensitive tumours as measured by PCNA immuno-
staining (A). Apoptosis, measured by the percent of active-caspase3-
positively stained tumour area, of cancer cells in the same tumour/liver
samples as in A (B).
Additional file 3: Angiogenesis (CD34 staining) of irbesartan-
sensitive tumours. Degree of angiogenic vessel formation (as measured
by CD34immuno- staining from animals bearing Irbesartan-sensitive
tumours
Abbreviations
ANG II: angiotensin II; ACE: angiotensin converting enzyme; AT1R:
angiotensin II type 1 receptor; AT2R: angiotensin II type 2 receptor; CRC:
colorectal cancer; VEGF: vascular endothelial growth factor; RAS: renin
angiotensin system.
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